BioLineRx Ltd.: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Mar 22, 2023 and accepted by EDGAR at Mar 22, 2023, 11:46 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$29.2m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$25.0m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$0.03 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$0.03 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$26.2m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2022-01-01 to 2022-12-31 | $131.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2022-12-31 | $10.6m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2022-12-31 | $52.0m | ifrs-full:CurrentAssets |
| Total assets | At period end2022-12-31 | $76.4m | ifrs-full:Assets |
| Current liabilities | At period end2022-12-31 | $10.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2022-12-31 | $25.5m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2022-12-31 | $50.8m | ifrs-full:Equity |
| Shares outstanding | At period end2022-12-31 | 922,958,942 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001178913-23-001091. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.